Media coverage about Rosetta Genomics (NASDAQ:ROSG) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Rosetta Genomics earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 47.6538786895899 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Separately, Barrington Research downgraded Rosetta Genomics from an “outperform” rating to a “market perform” rating in a research report on Monday, December 18th.
Rosetta Genomics (NASDAQ ROSG) remained flat at $$0.58 during trading hours on Friday. 63,498 shares of the company traded hands, compared to its average volume of 155,002. Rosetta Genomics has a 12 month low of $0.48 and a 12 month high of $6.72. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.10 and a quick ratio of 2.10.
Rosetta Genomics Company Profile
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).
Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.